We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+63.68%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.94B
AUM Growth
+$727M
Cap. Flow
+$234M
Cap. Flow %
7.95%
Top 10 Hldgs %
50.17%
Holding
105
New
24
Increased
24
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$134M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
3
TERN
Terns Pharmaceuticals
TERN
+$104M
4
ABVX
Abivax
ABVX
+$98.2M
5
MRK icon
Merck
MRK
+$72.7M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$104M
2
ASND icon
Ascendis Pharma A/S
ASND
+$87.8M
3
FOLD
Amicus Therapeutics
FOLD
+$76.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$70.3M
5
BDX icon
Becton Dickinson
BDX
+$60.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$16.4B
$37.3M 1.27%
175,000
-425,000
-71% -$87.8M
RAPP
27
Rapport Therapeutics
RAPP
$2.22B
$33.7M 1.15%
1,110,000
+160,000
+17% +$4.43M
SLDB icon
28
Solid Biosciences
SLDB
$857M
$32.8M 1.12%
5,815,000
+2,840,000
+95% +$15.4M
CLDX icon
29
Celldex Therapeutics
CLDX
$3.26B
$31.6M 1.08%
1,165,000
-40,000
-3% -$1.05M
SRRK icon
30
Scholar Rock
SRRK
$6.31B
$30.8M 1.05%
700,000
-800,000
-53% -$30M
KALV
31
DELISTED
KalVista Pharmaceuticals
KALV
$30.5M 1.04%
1,890,000
+1,140,000
+152% +$15.1M
VERA icon
32
Vera Therapeutics
VERA
$2.3B
$27.9M 0.95%
550,000
-210,000
-28% -$7.46M
XENE icon
33
Xenon Pharmaceuticals
XENE
$6.24B
$26.9M 0.91%
600,000
-500,000
-45% -$21M
LNTH icon
34
Lantheus
LNTH
$6.6B
$24M 0.81%
360,000
+190,000
+112% +$11.1M
RVMD icon
35
Revolution Medicines
RVMD
$42.1B
$23.5M 0.8%
295,000
-335,000
-53% -$22M
ZYME icon
36
Zymeworks
ZYME
$1.7B
$22.8M 0.77%
865,000
-900,000
-51% -$19.6M
IMCR icon
37
Immunocore
IMCR
$1.75B
$20.3M 0.69%
+585,000
New +$20.7M
UPB
38
Upstream Bio Inc
UPB
$374M
$19.5M 0.66%
+720,000
New +$17.9M
BBNX
39
Beta Bionics
BBNX
$635M
$18.3M 0.62%
600,000
– –
CBIO
40
Crescent Biopharma
CBIO
$610M
$17.8M 0.6%
+1,500,000
New +$19.1M
BCRX icon
41
BioCryst Pharmaceuticals
BCRX
$2.36B
$17.6M 0.6%
+2,250,000
New +$16.3M
PEN icon
42
Penumbra
PEN
$12.8B
$15.5M 0.53%
+50,000
New +$13.8M
GERN icon
43
Geron
GERN
$1.01B
$14.9M 0.51%
11,320,000
-5,905,000
-34% -$7.41M
RGEN icon
44
Repligen
RGEN
$9B
$13.6M 0.46%
83,000
-317,000
-79% -$49.7M
ZBH icon
45
Zimmer Biomet
ZBH
$18.8B
$13.5M 0.46%
+150,000
New +$14.2M
BMY icon
46
Bristol-Myers Squibb
BMY
$131B
$13.5M 0.46%
+250,000
New +$12M
GLUE icon
47
Monte Rosa Therapeutics
GLUE
$1.33B
$12.2M 0.41%
775,000
-25,000
-3% -$337K
FULC icon
48
Fulcrum Therapeutics
FULC
$288M
$10.7M 0.37%
+950,000
New +$9.67M
SVRA icon
49
Savara
SVRA
$1.19B
$9.68M 0.33%
1,606,000
-2,409,000
-60% -$11.8M
ENGN icon
50
enGene Therapeutics
ENGN
$121M
$9.53M 0.32%
1,055,000
+685,000
+185% +$5.49M
1
2
3 4 5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Vestal Point Capital held 105 positions worth $2.94B, up 33% from $2.21B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Vestal Point Capital deployed $234M of net new capital in Q4 2025, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Terns Pharmaceuticals: 4,500,000 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $104M trimmed.

  • Vestal Point Capital's largest Q4 2025 buy was Terns Pharmaceuticals: 4,500,000 shares worth $182M.
  • Vestal Point Capital added most to Arcellx in Q4 2025, an estimated $134M increase.
  • Vestal Point Capital's biggest Q4 2025 reduction was Nuvalent, cutting an estimated $104M.
  • Vestal Point Capital fully exited Amicus Therapeutics in Q4 2025, selling an estimated $76.8M.
  • Vestal Point Capital's ten largest holdings make up 50% of its $2.94B portfolio in Q4 2025.
  • Vestal Point Capital opened 24 new positions and closed 29 in Q4 2025.
  • Vestal Point Capital's portfolio value rose 33% quarter-over-quarter to $2.94B.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.